Low-intermediate dose testosterone replacement therapy by different pharmaceutical preparations improves frailty score in elderly hypogonadal hyperglycaemic patients

Aging Male

Volumn 16, Issue 2, 2013, Pages 33-37

  Strollo, Felice ^a   Strollo, Giovanna ^b   Morè, Massimo ^a   Magni, Paolo ^c   Macchi, Chiara ^c   Masini, Maria Angela ^d   Carucci, Iarba ^a   Celotti, Fabio ^c   Ruscica, Massimiliano ^c   Gentile, Sandro ^e  

^a INRCA   (Italy)

^b S Peter Hospital FBF   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

^e SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Elderly; Frailty; Hyperglycemia; Overweight; Testosterone treatment

Indexed keywords

GLUCOSE; HEMOGLOBIN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; TESTOSTERONE UNDECANOATE; UNDECANOIC ACID;

AGED; ANDROGEN THERAPY; ARTICLE; BODY MASS; CONTROLLED STUDY; ENERGY EXPENDITURE; FITNESS; FOLLOW UP; FRAIL ELDERLY; GAIT; GLUCOSE BLOOD LEVEL; GRIP STRENGTH; HUMAN; HYPOGONADISM; OBESITY; OPEN STUDY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; QUESTIONNAIRE; SCORING SYSTEM; TREATMENT DURATION; WAIST CIRCUMFERENCE; WALKING;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; AGED; AGING; BLOOD GLUCOSE; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HORMONE REPLACEMENT THERAPY; HUMANS; HYPERGLYCEMIA; HYPOGONADISM; MALE; MOTOR ACTIVITY; MUSCLE STRENGTH; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; QUALITY OF LIFE; RISK ASSESSMENT; TESTOSTERONE; TREATMENT OUTCOME;

EID: 84877991015     PISSN: 13685538     EISSN: 14730790     Source Type: Journal    
DOI: 10.3109/13685538.2013.773305     Document Type: Article

References (33)

1. Wang C, Nieschlag E, Swerdloff RS, et al. ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male 2009;12:5-12.
2. Wu FC, Tajar A, Beynon JM, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 2010;363:123-35.
3. Bassil N. Late-onset hypogonadism. Med Clin North Am 2011; 95:507-23, x.
4. Balzi D, Lauretani F, Barchielli A, et al. Risk factors for disability in older persons over 3-year follow-up. Age Ageing 2010;39:92-8.
5. Hyde Z, Flicker L, Almeida OP, et al. Low free testosterone predicts frailty in older men: the health in men study. J Clin Endocrinol Metab 2010;95:3165-72.
6. Travison TG, Nguyen AH, Naganathan V, et al. Changes in reproductive hormone concentrations predict the prevalence and progression of the frailty syndrome in older men: the concord health and ageing in men project. J Clin Endocrinol Metab 2011; 96:2464-74.
7. Cicero AF, Magni P, Lentini P, et al. Sex hormones and adipokines in healthy pre-menopausal, post-menopausal and elderly women, and in age-matched men: data from the Brisighella Heart study. J Endocrinol Invest 2011;34:e158-62.
8. Jones TH, Arver S, Behre HM, et al. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care 2011;34:828-37.
9. Cao J, Chen TM, Hao WJ, et al. Correlation between sex hormone levels and obesity in the elderly male. Aging Male 2012;15:85-9.
10. Cicero AF, Magni P, More M, et al. Metabolic syndrome, adipokines and hormonal factors in pharmacologically untreated adult elderly subjects from the Brisighella Heart Study historical cohort. Obes Facts 2012;5:319-26.
11. George JT, Millar RP, Anderson RA. Hypothesis: kisspeptin mediates male hypogonadism in obesity and type 2 diabetes. Neuroendocrinology 2010;91:302-7.
12. Dandona P, Dhindsa S. Update: hypogonadotropic hypogonadism in type 2 diabetes and obesity. J Clin Endocrinol Metab 2011;96: 2643-51.
13. Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2006;154:899-906.
14. Legros JJ, Meuleman EJ, Elbers JM, et al. Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study. Eur J Endocrinol 2009;160:821-31.
15. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-19.
16. Valenti G, Gontero P, Sacco M, et al. Harmonized Italian version of the Aging Males' Symptoms scale. Aging Male 2005;8:180-3.
17. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001; 56:M146-56.
18. Marin P, Holmang S, Gustafsson C, et al. Androgen treatment of abdominally obese men. Obes Res 1993;1:245-51.
19. Mårin P. Effects of androgens in men with the metabolic syndrome. Aging Male 1998;1:129-36.
20. Boyanov MA, Boneva Z, Christov VG. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male 2003;6:1-7.
21. Corona G, Monami M, Rastrelli G, et al. Testosterone and metabolic syndrome: a meta-analysis study. J Sex Med 2011; 8:272-83.
22. Saad F, Aversa A, Isidori AM, Gooren LJ. Testosterone as potential effective therapy in treatment of obesity in men with testosterone deficiency: a review. Curr Diabetes Rev 2012;8:131-43.
23. Tribess S, Virtuoso Junior JS, Oliveira RJ. Physical activity as a predictor of absence of frailty in the elderly. Rev Assoc Med Bras 2012;58:341-7.
24. Kalyani RR, Tian J, Xue QL, et al. Hyperglycemia and incidence of frailty and lower extremity mobility limitations in older women. J Am Geriatr Soc 2012;60:1701-7.
25. Kohn FM, Schill WB. A new oral testosterone undecanoate formulation. World J Urol 2003;21:311-15.
26. Yamaguchi K, Ishikawa T, Chiba K, Fujisawa M. Assessment of possible effects for testosterone replacement therapy in men with symptomatic late-onset hypogonadism. Andrologia 2011;43:52-6.
27. Makinen JI, Huhtaniemi I. Androgen replacement therapy in lateonset hypogonadism: current concepts and controversies - a mini-review. Gerontology 2011;57:193-202.
28. Schleich F, Legros JJ. Effects of androgen substitution on lipid profile in the adult and aging hypogonadal male. Eur J Endocrinol 2004;151:415-24.
29. Marks LS, Mazer NA, Mostaghel E, et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA 2006;296: 2351-61.
30. Coward RM, Simhan J, Carson 3rd CC. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy. BJU Int 2009;103:1179-83.
31. Vignozzi L, Morelli A, Sarchielli E, et al. Testosterone protects from metabolic syndrome-associated prostate inflammation: an experimental study in rabbit. J Endocrinol 2012;212:71-84.
32. Kiraly CL. Androgenic-anabolic steroid effects on serum and skin surface lipids, on red cells, and on liver enzymes. Int J Sports Med 1988;9:249-52.
33. Gasser RW. [Androgen therapy from the viewpoint of the internal medicine physician]. Wien Med Wochenschr 2001;151: 444-7.